ECSP10010142A - Nuevos anticuerpos especificos de los peptidos -amiloides y sus usos como agentes de diagnostico o drogas - Google Patents

Nuevos anticuerpos especificos de los peptidos -amiloides y sus usos como agentes de diagnostico o drogas

Info

Publication number
ECSP10010142A
ECSP10010142A EC2010010142A ECSP10010142A ECSP10010142A EC SP10010142 A ECSP10010142 A EC SP10010142A EC 2010010142 A EC2010010142 A EC 2010010142A EC SP10010142 A ECSP10010142 A EC SP10010142A EC SP10010142 A ECSP10010142 A EC SP10010142A
Authority
EC
Ecuador
Prior art keywords
peptides
amiloids
diagnosis
specific antibodies
new specific
Prior art date
Application number
EC2010010142A
Other languages
English (en)
Inventor
Eugeen Vanmechelen
Pierre Grognet
Nicolas Sergeant
Marie Gompel
Andre Delacourte
Luc Buee
Laurent Pradier
Veronique Blanchard-Bregeon
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010142(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of ECSP10010142A publication Critical patent/ECSP10010142A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a un anticuerpo monoclonal que se une específicamente a la región N-terminal de péptidos A?8-x, estando x comprendido desde 11 a 42, y que no reconoce ni A?1-40 ni A?1-42 y que presenta una elevada afinidad con respecto a péptidos A?8-x, tal como se determina mediante la formación de complejo inmunológico entre el anticuerpo monoclonal y el péptido A?8-x.
EC2010010142A 2007-10-29 2010-04-29 Nuevos anticuerpos especificos de los peptidos -amiloides y sus usos como agentes de diagnostico o drogas ECSP10010142A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119537 2007-10-29

Publications (1)

Publication Number Publication Date
ECSP10010142A true ECSP10010142A (es) 2010-07-30

Family

ID=38925731

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010142A ECSP10010142A (es) 2007-10-29 2010-04-29 Nuevos anticuerpos especificos de los peptidos -amiloides y sus usos como agentes de diagnostico o drogas

Country Status (27)

Country Link
US (1) US8343493B2 (es)
EP (1) EP2205633A1 (es)
JP (1) JP5421277B2 (es)
KR (1) KR20100097651A (es)
CN (1) CN101883792B (es)
AP (1) AP2957A (es)
AR (1) AR069085A1 (es)
AU (1) AU2008317705B2 (es)
CA (1) CA2703825A1 (es)
CL (1) CL2008003197A1 (es)
CO (1) CO6270369A2 (es)
CR (1) CR11396A (es)
EA (1) EA201070539A1 (es)
EC (1) ECSP10010142A (es)
HN (1) HN2010000880A (es)
IL (1) IL205398A0 (es)
MA (1) MA31793B1 (es)
MX (1) MX2010004660A (es)
MY (1) MY155144A (es)
NI (1) NI201000075A (es)
NZ (1) NZ585000A (es)
TN (1) TN2010000197A1 (es)
TW (1) TW200936605A (es)
UA (1) UA103602C2 (es)
UY (1) UY31433A1 (es)
WO (1) WO2009056490A1 (es)
ZA (1) ZA201002989B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
LT2436696T (lt) * 2007-01-05 2017-08-25 University Of Zurich Anti-beta-amiloido antikūnas ir jo panaudojimas
JP5810413B2 (ja) 2008-12-19 2015-11-11 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗アルファシヌクレイン自己抗体
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
TW201144437A (en) 2010-03-03 2011-12-16 Boehringer Ingelheim Int A-beta binding polypeptides
EP2511296A1 (en) * 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
US9617332B2 (en) 2012-05-10 2017-04-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Conformational-specific antibodies against A[β] oligomers
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
AU2016354688B2 (en) * 2015-11-09 2021-12-16 The University Of British Columbia Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
US20190151476A1 (en) 2016-07-19 2019-05-23 Duke University Therapeutic applications of cpf1-based genome editing
JOP20200041A1 (ar) 2017-08-22 2020-02-20 Biogen Ma Inc تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2023111168A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag A novel antibody for detection of amyloid beta 42 (aβ42)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1911765A3 (en) * 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
WO2009056490A1 (en) 2009-05-07
CL2008003197A1 (es) 2010-01-15
CN101883792B (zh) 2014-08-27
AP2010005249A0 (en) 2010-06-30
HN2010000880A (es) 2014-03-10
EA201070539A1 (ru) 2010-10-29
IL205398A0 (en) 2010-12-30
NI201000075A (es) 2010-09-23
MA31793B1 (fr) 2010-10-01
ZA201002989B (en) 2011-07-27
US8343493B2 (en) 2013-01-01
AR069085A1 (es) 2009-12-30
EP2205633A1 (en) 2010-07-14
UA103602C2 (ru) 2013-11-11
AU2008317705A1 (en) 2009-05-07
TW200936605A (en) 2009-09-01
CR11396A (es) 2012-10-18
AU2008317705B2 (en) 2014-06-05
CA2703825A1 (en) 2009-05-07
UY31433A1 (es) 2009-05-29
MX2010004660A (es) 2010-07-30
KR20100097651A (ko) 2010-09-03
AP2957A (en) 2014-08-31
CO6270369A2 (es) 2011-04-20
JP5421277B2 (ja) 2014-02-19
JP2011502139A (ja) 2011-01-20
TN2010000197A1 (en) 2011-11-11
CN101883792A (zh) 2010-11-10
MY155144A (en) 2015-09-15
NZ585000A (en) 2012-08-31
US20110059092A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
ECSP10010142A (es) Nuevos anticuerpos especificos de los peptidos -amiloides y sus usos como agentes de diagnostico o drogas
ES2500066T3 (es) Anticuerpos frente a ferroportina y métodos de uso
CL2019000100A1 (es) Anticuerpos contra tim3 y suso de los mismos.
SG10201807877TA (en) Hybrid immunoglobulin containing non-peptidyl linkage
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
CR11374A (es) Proteinas humanas de union a antigenos del gm-csf
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
CR20120127A (es) Anticuerpos monoclonales
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
ECSP14013307A (es) Genzyme corporation
AR095432A1 (es) Proteínas de unión a antígeno
SG178886A1 (en) Humanized anti-cdcp1 antibodies
GT200600186A (es) Agentes de unión
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
GT200900043A (es) Anticuerpos monoclonales humanos especificos para light humano antagonistas
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
TN2014000120A1 (en) Cd27l antigen binding proteins
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
TR201819828T4 (tr) Anti-fosfolipaz d4 antikoru.
PE20181199A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
MX343873B (es) Ensayo de diagnostico de anticuerpo.
GB0611708D0 (en) Novel antibodies against prion protein and uses thereof